Prostate Cancer Quarterly Benchmarks Report

Fiscal Year 2012 2nd Quarter Report

Jurisdiction/Program: ALL

Sponsor: CRF

			Period:	7/1-9/30	10/1-12/31	1/1-3/31	4/1-6/30	7/1/-6/30
			Run Date:	01/13/2012	04/06/2012			
Category	No.	Indicator	Standard	FY12 1Q	FY12 2Q	FY12 3Q	FY12 4Q	FY12 Total
Screening Priority Population	1	Percent of prostate cancer screenngs with both PSA and DRE	≥80%	96.9	100.0			
Case Management Among Program-eligible Clients	2	Percent of prostate cancer screenings* with abnormal findings/needs further evaluation to rule out cancer with a diagnosis status of 'Complete'	≥80%	100.0	No Data			
	3	Percent of prostate cancer screenings* with abnormal findings/needs further evaluation to rule out cancer with date of diagnosis within 90 days of screening among those with diagnosis status of 'Complete'	≥80%	100.0	No Data			
	4	Percent of prostate cancers diagnosed with treatment started	≥80%	No Data	50.0			
	5	Percent of prostate cancers with treatment started within 60 days of diagnosis among those who started treatment	≥80%	No Data	100.0			
	6	Percent of prostate cancers with stage information among clients diagnosed with cancer who had surgery	≥80%	80.0	100.0			
Notification	7	Percent of PSA results received by the program within 28 days of test	≥80%	100.0	100.0			
	8	Percent of men ever notified of screening* results by program	≥95%	100.0	100.0			
	9	Percent of men with abnormal findings/needs further evaluation to rule out cancer, were notifed of results, and were notified by program within 7 days of when screening^ results received by program	≥80%	100.0	100.0			

*Screening means screened with Prostate Specific Antigen (PSA) and/or Digital Rectal Exam (DRE) *Screening means screened with Prostate Specific Antigen (PSA) or PSA and Digital Rectal Exam (DRE)